Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319864 · ClinicalTrials.gov registry record · Phase 1
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01319864 is a Phase 1 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 20 participants.
The verdict
NCT01319864, a Phase 1 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs-cytarabine and etoposide. We want to find out what effects, good and /or bad, this combination of drugs has on leukemia. Plerixafor is a drug that blocks a receptor on the leukemia cell, which prevents it from staying in the bone marrow where it can be resistant to chemotherapy. Plerixafor is FDA approved for mobilizing stem cells from the bone marrow in preparation for an autologous stem cell transplant. Cytarabine and etoposide have been used as part of standard chemotherapy for ALL and AML. However, the use of plerixafor with cytarabine and etoposide in pediatric patients with relapsed or refractory ALL, AML and MDS is considered experimental.
Interventions
- DRUG Plerixafor Dose Escalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01319864
The ClinicalTrials.gov registry entry for NCT01319864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plerixafor Dose Escalation is the first listed.
NCT01319864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01319864 about?
NCT01319864 is a clinical study titled "POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients". In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs-cytarabine and etoposide. We want to find out what effects, good and /or bad, this combination of drugs has on leukemia. Plerixafor is a drug that bloc...
What is the current status of trial NCT01319864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-03. Estimated completion is 2016-06-28.
What interventions are being tested in trial NCT01319864?
The interventions under investigation include: Plerixafor Dose Escalation (DRUG).
Who is sponsoring clinical trial NCT01319864?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.